Document:

Restated Credit Agreement

 Exhibit 10.51 
 RESTATED CREDIT AGREEMENT 
 This Restated Credit Agreement (this
“Agreement”) is entered into between MARK OMAN (“Oman”) and JOHN PAPPAJOHN (“Pappajohn”) (collectively the “Lender”), and CANCER GENETICS, INC., a Delaware corporation (the “Company”), as of
October 17, 2012. 
 WHEREAS, the Company desires that the Lender provide to it credit in the principal amount of
Three Million Dollars ($3,000,000); 
 WHEREAS, the Lender previously provided credit to the Company in the principal
amount of Two Million Dollars ($2,000,000) pursuant to a Credit Agreement dated as of August 27, 2012 (the “Original Credit Agreement”) and a note, warrant and other documents dated that date (the “Original Ancillary
Documents”); and 
 WHEREAS, the Lender is willing to provide such $3,000,000 credit (inclusive of amounts
previously advanced) to the Company on the terms and conditions hereof; 
 NOW, THEREFORE, for good and valuable
consideration, the parties hereto agree as follows: 
 1. Loan and Note. The Lender shall advance to the Company on the
date hereof the aggregate amount of One Million Dollars ($1,000,000), $250,000 by Oman and $750,000 by Pappajohn. The Company acknowledges prior receipt of $1,000,000 from Pappajohn on or about July 18, 2012 and $1,000,000 from Oman on or about
August 27, 2012. Upon execution of this Agreement and funding of the new loan, the Company shall execute and deliver to each Lender a Promissory Note in substantially the form of Exhibit A attached hereto (collectively the
“Note”), dated the date of the advance, to evidence the terms and conditions of the Company’s repayment of, and other obligations with respect to, the credit advanced by Lender (the “Loan”) to the Company hereunder and
thereunder. Any prior promissory notes issued by the Company to the Lender pursuant to the Original Credit Agreement shall be deemed repaid, rescinded and null and void. Lender covenants to deliver and return all such original notes which were part
of the Original Ancillary Documents to the Company for cancellation immediately. 
 2. Warrant. (a) As additional
consideration for extending the credit and making the Loan set forth in this Agreement, on or about the date hereof, the Company shall issue and deliver to the Lender Stock Purchase Warrants (the “Warrant”) to purchase 572,549 shares of
common stock in the aggregate (or 256,863 warrants for Oman and 315,686 warrants for Pappajohn). Any prior warrants issued by the Company to the Lender pursuant to the Original Credit Agreement shall be rescinded and be null and void. Lender
covenants to deliver and return all such original warrants which were part of the Original Ancillary Documents to the Company for cancellation immediately. 
 (a) If a registration statement for an initial public offering of the Company’s common stock (“IPO”) has not been declared effective by the Securities and Exchange Commission
(“SEC”) prior to November 27, 2012, then the Company shall issue and deliver to the Lender additional Warrants as follows: warrants to purchase 14,706 shares of the Company’s common stock to Oman and warrants to purchase 20,589
shares to Pappajohn (11,765 warrants per $1 million advanced). 

 (b) If a registration statement for an IPO has not been declared effective by the SEC prior
to February 22, 2013, then the Company shall issue and deliver to the Lender an additional Warrants as follows: warrants to purchase 14,706 shares of the Company’s common stock to Oman and warrants to purchase 20,589 shares to Pappajohn
(11,765 warrants per $1 million advanced). 
 (c) All Warrants shall expire on October 17, 2022, and have an exercise price
equal to $8.50 per share (which price shall be reduced to the price paid per share by the public in the IPO if less), and shall be in the form of Exhibit B attached hereto. 
 All share numbers in Section 2 shall be subject to equitable adjustment in the event of any stock split, stock combination, recapitalization or similar transaction between the date hereof and the
issuance of the respective Warrant. 
 3. Use of Proceeds. The Company covenants to use the proceeds for the Loan for
current operations and for expenses related to the IPO process, including auditing, legal, filing and printing fees. 
 4.
Joinder to Stockholders’ Agreement. In the event that the Warrant (or any portion thereof) is exercised prior to an IPO, and shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company are issued
pursuant thereto (the “Lender’s Warrant Shares”), the Lender and the Company shall execute and deliver to each other a Joinder Agreement (the “Joinder Agreement”) in substantially the form of Exhibit C attached
hereto, pursuant to which the Lender shall become a party to the Amended and Restated Stockholders’ Agreement, dated as of April 13, 2010, by and among the Company and the individuals or entities listed on Schedule I, Schedule II
and Schedule III thereto (as may be amended or modified from time to time, the “Stockholders’ Agreement”) 

5. Registration Rights Agreement. In connection with the delivery to the Lender of the Note and Warrant, the Company and the Lender
shall execute and deliver to each other the Registration Rights Agreement (the “Lender’s Registration Rights Agreement”) in substantially the form of Exhibit D attached hereto. The Lender will also enter into a Lock-Up
Agreement in the form of Exhibit E attached hereto and other documents reasonably requested by the Company to permit it to attempt to arrange for its IPO. 
 6. Definitions. Capitalized terms not otherwise defined herein shall have the following meanings: 
 “Event of Default” means (i) any material breach by the Company of a warranty or representation contained in this Agreement or any material default by the Company in the performance of any
of its obligations hereunder, or (ii) the occurrence of any event that would constitute a material breach by the Company of any representation or warranty, or a material default by the Company in the performance of any of its obligation under,
the Note or any of the other Transaction Documents; provided, however, that if the Company has a right to cure such breach or default as provided in the agreement with respect to which such breach or default arises, then the Lender shall have first
been given any notice as provided for in such agreement and the Company shall have failed to take action within the time period set forth therein to cure or remedy such breach or default. 

  
 -2-

 “Lender’s Warrant Shares” means the shares of Common Stock delivered, or
deliverable, upon the due exercise of the Warrant. 
 “Maturity Event” means February 26, 2014. 

“Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 “Transaction Documents” means the Note, the Warrant, and the Lock-Up Agreement. 

7. Loan Maturity and Penalty Interest. The entire outstanding balance of the Note shall become due and payable upon the occurrence
of a Maturity Event or upon the occurrence of certain other events, all as more specifically provided for in the Note. 
 8.
Company Warranties and Representations. The Company hereby makes the following representations and warranties to the Lender: 
 8.01 Organization, Good Standing and Qualification. The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the state of Delaware and has all
requisite corporate power and authority to carry on its business as now conducted and to own its properties. The Company is duly qualified to do business as a foreign corporation and is in good standing in each jurisdiction in which the conduct of
its business or its ownership or its leasing of property makes such qualification or licensing necessary, unless the failure to so qualify would not have a material adverse effect on the business or financial condition of the Company. 

8.02 Authorization. The Company has full power and authority with respect to, and has taken all requisite action on the part of the
Company, its officers, directors and stockholders necessary for (i) the authorization, execution and delivery of this Agreement and the Transaction Documents, (ii) the authorization of the performance of all obligations of the Company
under this Agreement and the Transaction Documents, and (iii) the authorization, issuance (or reservation for issuance) and delivery of the Lender’s Warrant Shares deliverable upon due exercise of the Warrant. This Agreement and the
Transaction Documents constitute the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium
and similar laws of general applicability, relating to or affecting creditors’ rights generally. 
 8.03
Capitalization. 
 (a) Except as set forth in Schedule 8.03: The authorized capital of the Company consisted,
immediately prior to August 21, 2012, of, (i) 24,000,000 shares of Common Stock, of which 6,730,621 shares are issued and outstanding; and (ii) three series of preferred stock, $0.0001 par value per share (the “Preferred
Stock”), consisting of 588,000 shares designated as Series A Convertible Preferred Stock, of which 52,926 pre-split shares are issued 

  
 -3-

 
and outstanding, 2,000,000 shares designated as Series B Convertible Preferred Stock, of which 1,821,600 shares are issued and outstanding and 1,764,000 shares designated as Series A-1
Preferred Stock, of which 1,604,295 shares are issued and outstanding. All of the issued and outstanding shares of the Company’s capital stock are duly authorized and validly issued and are fully paid, and nonassessable. No Person is entitled
to pre-emptive or similar statutory or contractual rights with respect to any securities of the Company. The holders of the Preferred Stock have certain anti-dilution protections which may be triggered by this transaction depending on the IPO price.

 (b) Except as set forth in Schedule 8.03: The Company has reserved 3,500,000 shares of Common Stock, in the
aggregate, for issuance pursuant to its two Stock Option Plans (the “Stock Plan”). Of such reserved shares of Common Stock, 191,000 shares have been issued and, immediately prior to the date hereof, options to purchase 2,366,700 shares
have been granted under the Stock Plan and are currently outstanding and options to purchase 400,000 shares have been granted outside of the Stock Plan and are currently outstanding. Immediately prior to the date hereof, there were issued and
outstanding unexercised warrants to purchase, in the aggregate, 4,884,063 shares of Common Stock. Immediately prior to the date hereof, there were convertible promissory notes with an aggregate principal balance of $4.0 million issued and
outstanding. Except as otherwise set forth in this subsection (b) and as contemplated by the Transaction Documents, there are no unexercised and outstanding warrants, options, convertible securities or other rights, agreements or arrangements
of any character under which the Company is or may be obligated to issue any equity securities of any kind. Other than the Transaction Documents, the Investors’ Rights Agreement and the Stockholders’ Agreement, there are no voting
agreements, buy-sell agreements, option or right of first purchase agreements or other agreements of any kind among the Company and any of its security holders relating to the securities of the Company. Other than the Investors’ Rights
Agreement and the Lender’s Registration Rights Agreement, the Company has not granted any Person the right to require the Company to register any of its securities under the 1933 Act, whether on a demand basis or in connection with the
registration of securities of the Company for its own account or for the account of any other Person. The holders of certain warrants have certain anti-dilution protections which may be triggered by this transaction depending on the IPO price.

 8.04 Corporate Governance Documents. The Amended and Restated Certificate of Incorporation of the Company (the
“Certificate of Incorporation”) filed with the Office of the Delaware Secretary of State on December 5, 2011, remains in full force and affect and has not been amended since the date of that filing. The Stockholders’ Agreement,
including any amendments or supplements thereto, provided to the Lender prior to the date are true and complete copies of such agreements, which agreements remain in full force and effect. 

8.05 Valid Issuance. The Warrant has been duly and validly authorized and, upon the due exercise of the Warrant and conversion of
the Note, the Shares issued will be validly issued, fully paid and non-assessable, and shall be free and clear of all liens, claims, encumbrances and restrictions, except for restrictions on transfer set forth in the Transaction Documents or imposed
by applicable securities laws. The Company has reserved a sufficient number of shares of its authorized and un-issued Common Stock for issuance upon exercise of the Warrants or conversion of the Note. 

  
 -4-

 8.06 Consents. The execution and delivery of, and the performance by the Company of
its obligations under, this Agreement and the Transaction Documents do not, and in the event of the due exercise of the Warrant, the issuance of the Lender’s Warrant Shares, will not, require any consent of, action by or in respect of, or
filing with, any Person, governmental body, agency, or official other than filings that have been made pursuant to applicable state securities laws and post-sale filings pursuant to applicable state and federal securities laws which the Company
undertakes to file within the applicable time periods. 
 8.07 No Conflict, Breach, Violation or Default. The execution
and delivery of, and the performance by the Company of its obligations under, this Agreement and the Transaction Documents and the issuance and delivery of the Lender’s Warrant Shares upon exercise of the Warrant will not conflict with or
result in a breach or violation of any of the terms and provisions of, or constitute a default under (i) the Company’s Certificate of Incorporation or Bylaws, each as in effect on the date hereof or thereof, or (ii)(a) any statute,
rule, regulation or order of any governmental agency or body or any court, domestic or foreign, having jurisdiction over the Company or any of its assets or properties, or (b) any agreement or instrument to which the Company is a party or by
which the Company is bound or to which any of its assets or properties is subject. 
 8.08 Litigation. There are no
pending material actions, suits or proceedings against or affecting the Company or any of its properties; and to the Company’s knowledge, no such actions, suits or proceedings are threatened or contemplated. 

9. Lender’s Representations and Warranties. The Lender hereby makes the following representations and warranties to the
Company: 
 9.01 Authorization. Each Lender has full power and authority with respect to, (i) the authorization,
execution and delivery of this Agreement and the Transaction Documents and (ii) the authorization of the performance of all obligations of the Lender hereunder or thereunder. This Agreement and the Transaction Documents constitute the legal,
valid and binding obligations of the Lender, enforceable against the Lender in accordance with their respective terms (to the extent the Lender is a party thereto), subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium
and similar laws of general applicability, relating to or affecting creditors’ rights generally. 
 9.02 Consents.
The execution and delivery of, and the performance by the Lender of its obligations under, this Agreement and the Transaction Documents do not and will not, require any consent of, action by or in respect of, or filing with, any Person, governmental
body, agency, or official. 
 9.03 No Conflict, Breach, Violation or Default. The execution and delivery of, and the
performance by the Lender of its obligations under, this Agreement and the Transaction Documents will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default under (i) any statute,
rule, regulation or order of any governmental agency or body or any court, domestic or foreign, having jurisdiction over the Lender or any of its assets or properties, or (ii) any agreement or instrument to which the Lender is a party or by
which the Lender is bound or to which any of its assets or properties is subject. 

  
 -5-

 10. Mandatory Conversion. Each Lender shall convert the principal amount of its Note
as of the closing of an IPO into shares of the Company’s common stock, effective upon closing, at a conversion price equal to the lesser of (i) $8.50 or (ii) the price paid by the public in the IPO. The $8.50 price shall be subject to
adjustment for any stock splits, stock combinations, recapitalizations or similar transactions between the date hereof and consummation of the IPO in a manner consistent with Section (f)(1) and f(2) of the Warrant 

11. Lender Cooperation. The Lender agrees to execute at the request of the Company (a) a Lock Up Agreement referred to above
or as otherwise requested by any underwriter for the IPO and any assignments thereof and (b) documents reasonably requested by the Company’s existing lenders with respect to payment and priority of the obligations created hereunder. The
Lender reaffirms all Lock Up agreements or similar documents executed by them and agree that they will operate in favor of any underwriter of an IPO for the Company. 
 12. Negative Pledge. The Company will not, without Lender’s consent, create any mortgage, lien, or encumbrance on, or pledge of, any of its property or assets, or file or permit the filing of
any financing statement under the Uniform Commercial Code, while this Note is outstanding; provided however that the Section 12 shall not prevent or restrict the creation of (a) purchase money mortgages or security interests to secure the
purchase price of any assets or property or to secure indebtedness incurred solely for the purpose of financing the acquisition of any such property, (b) leases of real or personal property, whether operating leases or capital leases, where the
collateral consists solely of the real or personal property being leased, (c) mortgages or security interests existing on property or assets at the time of the acquisition of the property or assets by the Company; (d) refunding or
extension of mortgages or liens existing at the date hereof or any extensions or continuation statements file with respect to existing indebtedness for amounts not exceeding the original principal amount of the indebtedness refunded or extended;
(e) tax liens, (f) landlords’ liens, mechanics’ liens, materialmens’ liens or other liens created by the operation of law; (g) liens resulting from partial payments under government contracts, or (h) other liens
and encumbrances in respect of property or assets of the Company which are incidental to the conduct of the business of the Company, which were not incurred in connection with the borrowing of money or obtaining credit and which do not materially
detract from the property and assets of the Company. 
 13. Notices. All notices and other communications given or made
pursuant to this Agreement, pursuant to the Note, or pursuant to any of the other Transaction Documents that either incorporate the notice provisions hereof by reference or that fail to contain provisions for the manner of giving notice thereunder,
shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or: (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail or facsimile during normal business hours of the
recipient, and if not sent during normal business hours, then on the recipient’s next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one
(1) business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their
address as set forth beneath their signature hereto, or to such e-mail address, facsimile number or address as subsequently modified by written notice given in accordance with this Section. 

  
 -6-

 14. Lender’s Legal Fees. The Company shall reimburse Lender up to $10,000 for
the reasonable legal fees and costs of the Lender’s legal counsel in connection with the preparation and review of this Agreement, the Transaction Documents and the transactions contemplated therein. The Company shall make such reimbursement
within 10 days of Lender’s delivery to the Company of a copy of any invoice from Lender’s counsel to Lender with respect to such legal fees and costs. 
 15. Costs of Collection. If the Note is not paid when due, whether at maturity or by acceleration, the Company agrees to pay all reasonable costs of collection, including but not limited to
reasonable attorneys’ fees and reasonable expenses incurred by Lender on account of such collection, whether or not suit is commenced . 
 16. Amendments and Waiver. Unless otherwise specifically stated herein, any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or
in a particular instance and either retroactively or prospectively), with the written consent of the Lender and the Company. No waivers of or exceptions to any term, condition or provision of this Agreement, in any one or more instances, shall be
deemed to be, or construed as, a further or continuing waiver of any such term, condition or provision. 
 17. Entire
Agreement. This Agreement embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings relating to the subject matter hereof.

 18. Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity
or enforceability of any other provisions of this Agreement. 
 19. Governing Law. This Agreement shall be construed and
enforced in accordance with the laws of the State of Delaware without regard to conflicts of law principles. 
 20. Successors
and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall be binding upon, and inure to the benefit of, the respective representatives, successors and assigns of the parties; provided, however, that the
Company may not assign this Agreement without the consent of the Lender except in connection with an assignment by operation of law pursuant to a merger that constitutes a Maturity Event. 

21. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. 

  
 -7-

 IN WITNESS WHEREOF, each party has executed, or caused to be executed by a duly
authorized individual, this Agreement as of the date first set forth above. 
  

							
		 	COMPANY 
		
		 	CANCER GENETICS, INC.
				
		 	By:	 	 	 	 
		 		 	Name: Panna Sharma
		 		 	Title: President & CEO
				
		 		 	Address:	 	
		 		 	201 Route 17 North, 2nd Floor
		 		 	Rutherford, New Jersey 07070
		 		 	Attention: Panna Sharma
			
		 		 	Facsimile: 201-528-9201
		 		 	E-mail: psharma@cancergenetics.com
		
		 	LENDER
				
		 	 	 	 	 	 
		 	Mark Oman
				
		 		 	Address:	 	
				
		 		 	 	 	 
				
		 		 	 	 	 
				
		 		 	Attention:	 	 
				
		 		 	Facsimile:	 	 
				
		 		 	E-mail:	 	 
				
		 	 	 	 	 	 
		 	John Pappajohn
				
		 		 	Address:	 	
				
		 		 	 	 	 
				
		 		 	 	 	 
				
		 		 	Facsimile:	 	 
				
		 		 	E-mail:	 	 

  

  
 -8-

 Schedule 8.03 

Pending Option Grants 

The Board of directors has approved the issuance of an aggregate of 235,500 stock options to certain employees and directors upon the effectiveness of
the IPO and at an exercise price equal to the IPO price. 

  
 -9-Form of Restated Promissory Note

 Exhibit 10.52 
 RESTATED PROMISSORY NOTE 
  

			
		 	October 17, 2012

 FOR VALUE RECEIVED, Cancer Genetics, Inc., a Delaware corporation (“Borrower”), hereby
promises to pay to the order of                                  or his assigns,
the aggregate amount of the loan funded by Lender from time to time, the principal amount of
                                (the “Loan”), as set forth in that certain
Restated Credit Agreement between Lender and Borrower dated as of this date (the “Credit Agreement”), together with interest on such portions thereof as shall from time to time remain unpaid (the “principal balance”) at the
Contract Rate (as defined below) per annum, commencing on the date hereof, and until paid in full. 
 Borrower shall pay all
interest accrued on the principal amounts of the Loan borrowed hereunder on the first day of any calendar month while any amounts borrowed hereunder remain outstanding, commencing November 1, 2012, and shall pay all accrued interest and the
outstanding principal of all amounts borrowed hereunder immediately upon the occurrence of a Maturity Event, as that term is defined in the Credit Agreement. The payment obligation is subject to Borrower’s obligation to convert the Loan to
common stock of the Borrower under the circumstances set forth in the Credit Agreement. 
 After a Maturity Event or an Event of
Default (as that term is defined in the Credit Agreement), interest shall accrue on the unpaid balance of this Note at the rate of 12% per annum. 
 The Borrower may pre-pay all or any amount of principal or interest due under this Note only with the prior written consent of the Lender. 

Interest shall be computed on the principal balance on a daily rate basis of 1/365 of the annual rate. All payments shall be applied
first to interest on the principal balance at the rate herein specified and then to principal. The “Contract Rate” shall mean the sum of (a) the Prime Rate, as reported in the Wall Street Journal, on the first business day of each
calendar quarter plus (b) 6.25%. The Prime Rate on the date hereof is 3.25%, so that the Contract Rate is initially 9.50%. The Contract Rate shall adjust on the first day of each calendar quarter effective for the ensuing quarter. 

This Note is one of a series of notes delivered pursuant to the terms of the Credit Agreement, and any notice required hereunder may be
given in the manner that notices are given as provided for in the Credit Agreement. 
 At the option of the holder of this Note,
the unpaid principal balance and all accrued but unpaid interest shall become immediately due and payable, without notice or demand, upon the occurrence at any time of (1) the failure of Borrower to pay any amount of principal or interest when
the same becomes due under this Note, provided Borrower has received written notice of such default and has failed to cure the same within ten (10) days of the receipt of such notice, (2) the making of an assignment for the benefit of
creditors by Borrower, the appointment of a receiver for all or substantially all of the property of Borrower, or the filing by Borrower of a 

 
petition in bankruptcy or other similar proceeding under law for relief of debtors, (3) the filing against Borrower of a petition in bankruptcy or other similar proceeding under law for
relief of debtors, provided that such petition is not vacated or discharged within ninety (90) days after the filing thereof, (4) the dissolution of Borrower, or (5) the occurrence of any Event of Default, as that term is defined in
the Credit Agreement. 
 Waiver of any default of any kind in the performance of Borrower’s obligations under this Note
shall not constitute a waiver of any other default of Borrower’s obligations under this Note. 
 Without affecting the
liability of any maker or any endorser or surety, Lender may, without notice, renew or extend the time of payment, accept partial payments or agree not to sue any party liable to it. Presentment, protest, demand, and notice of dishonor are waived.

 If this Note is not paid when due, whether at maturity or by acceleration, Borrower and all endorsers, sureties and
guarantors agree to pay all reasonable costs of collection, including but not limited to reasonable attorneys’ fees and reasonable expenses incurred by Lender on account of such collection, whether or not suit is commenced. 

This Note shall be governed by and construed, interpreted and enforced in accordance with the laws of the State of Delaware. 

This Note shall automatically be converted into shares of Common Stock of the Borrower upon the terms and subject to the conditions set
forth in the Credit Agreement. This Note is issued in replacement of a promissory note in the principal sum of $1 million previously issued by Borrower to the holder, which prior note is deemed repaid, rescinded and null and void by reason of
issuance and acceptance of this Note. 
  

			
	BORROWER:
	
	 Cancer Genetics, Inc.,
 a Delaware corporation

		
	By:	 	 
	Name:	 	Panna Sharma
	Its:	 	President & CEO

  
 -2-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]